Toxic epidermal necrolysis associated with denileukin diftitox (DAB₃₈₉IL-2) administration in a patient with follicular large cell lymphoma

References

• Dang N H, Hagemeister F, Pro B, McLaughlin P, Romaguera J E, Jones D, et al. Phase II study of denileukin diftitox for relapsed/refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2004; 22: 4095–4102
   PubMed Web of Science ®Google Scholar
• Walker P, Dang N H. Denileukin diftitox as novel targeted therapy in non-Hodgkin's lymphoma. Clin J Oncol Nursing 2004; 8: 169–174
   PubMedGoogle Scholar
• Olsen E, Duvic M, Frankel A, Kim Y, Martin A, Vonderheid E, et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001; 19: 376–388
   PubMed Web of Science ®Google Scholar
• Frankel A E, Fleming D R, Powell B L, Gartenhaus R. DAB389IL-2 (ONTAK) fusion protein therapy of chronic lymphocytic leukemia. Expert Opin Biol Ther 2003; 3: 179–186
   PubMed Web of Science ®Google Scholar
• Roujeau J C, Kelly J P, Naldi L, Rzany B, Stern R S, Anderson T, et al. Medication use and the risk of Stevens–Johnson syndrome or toxic epidermal necrolysis. New Engl J Med 1995; 333: 1600–1607
   PubMed Web of Science ®Google Scholar
• Roujeau J C, Stern R S. Severe adverse cutaneous reactions to drugs. New Engl J Med 1994; 331: 1272–1285
   PubMed Web of Science ®Google Scholar
• Rzany B, Correia O, Kelly J P, Naldi L, Auquier A, Stern R. Risk of Stevens–Johnson syndrome and toxic epidermal necrolysis during the first weeks of antiepileptic therapy: a case-control study. Lancet 1999; 353: 2190–2194
   PubMed Web of Science ®Google Scholar
• Talpur R, Apisarnthanarax N, Ward S, Duvic M. Treatment of refractory peripheral T-cell lymphoma with denileukin diftitox (ONTAK). Leuk Lymphoma 2002; 43: 121–126
   PubMed Web of Science ®Google Scholar
• Foss F M, Bacha P, Osann K E, Demierre M F, Bell T, Kuzel T. Biological correlates of acute hypersensitivity events with DAB (389) IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication. Clin Lymphoma 2001; 4: 298–302
   Google Scholar
• Revuz J, Penso D, Roujeau J C, Guillaume J C, Payne C R, Wechsler J, Touraine R. Toxic epidermal necrolysis: clinical findings and prognosis factors in 87 patients. Arch Dermatol 1987; 123: 1160–1165
   PubMed Web of Science ®Google Scholar
• Wolkenstein P, Carriere V, Charue D, Bastuji-Garin S, Revuz J, Roujeau J C, et al. A slow acylator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Stevens–Johnson syndrome. Pharmacogenetics 1995; 5: 255–258
   PubMedGoogle Scholar
• Wolkenstein P, Charue D, Laurent P, Revuz J, Roujeau J C, Bagot M. Metabolic predisposition to cutaneous adverse drug reactions: role in toxic epidermal necrolysis caused by sulfonamides and anticonvulsants. Arch Dermatol 1995; 131: 544–551
   PubMed Web of Science ®Google Scholar
• Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282: 490–493
   PubMed Web of Science ®Google Scholar
• Wolkenstein P, Revuz J. Toxic epidermal necrolysis. Dermatol Clin 2000; 18: 485–495
   PubMed Web of Science ®Google Scholar
• Rocha J L, Kondo W, Baptista M I. Uncommon vancomycin-induced side effects. Braz J Infect Dis 2002; 6: 196–200
   PubMedGoogle Scholar
• Hsu S L. Biopsy-proved tubulointerstitial nephritis and toxic epidermal necrolysis associated with vancomycin. Pharmacotherapy 2001; 21: 1233–1239
   PubMed Web of Science ®Google Scholar
• Vidal C, Gonzalez A Quintela, Fuente R. Toxic epidermal necrolysis due to vancomycin. Ann Allergy 1992; 68: 345–347
   PubMedGoogle Scholar
• Armstrong A, Fazeli A, Yeh S W, Mackool B T, Liu V. Vancomycin-induced linear IgA disease manifesting as bullous erythema multiforme. J Cutan Pathol 2004; 31: 393–397
   PubMed Web of Science ®Google Scholar
• Richards S, Hall S, Yokel B, Whitmore S E. A bullous eruption in an elderly woman. Arch Dermatol 1995; 131: 1447–1452
   PubMedGoogle Scholar
• Joshi S, Scott G, Looney R J. A successful challenge in a patient with vancomycin-induced linear IgA dermatosis. Annal Allergy Asthma Immunol 2004; 93: 101–103
   PubMed Web of Science ®Google Scholar
• Kuechle M K, Stegemeir E, Maynard B, Gibson L E, Leijerman K M, Peters M S. Drug-induced linear IgA bullous dermatosis: report of six cases and review of the literature. J Am Acad Dermatol 1994; 30: 187–192
   PubMed Web of Science ®Google Scholar
• Delbaldo C, Chen M, Friedli A, Prins C, Desmeules J, Saurat J H, et al. Drug-induced epidermolysis bullosa aquisita with antibodies to type VII collagen. J Am Acad Dermatol 2002; 46: S161–S164
   PubMed Web of Science ®Google Scholar
• Mofid M Z, Costarangos C, Bernstein B, Wong L, Monster A, Nousari H C. Drug-induced linear immunoglobulin A bullous disease that clinically mimics toxic epidermal necrolysis. J Burn Care Rehabil 2000; 21: 246–247
   PubMedGoogle Scholar
• Waldman M A, Black D R, Callen J P. Vancomycin-induced linear IgA bullous disease presenting as toxic epidermal necrolysis. Clin Exp Dermatol 2004; 29: 633–636
   PubMed Web of Science ®Google Scholar
• Argenyi Z B, Bergfeld W F, Valenzuela R, McMahon J T, Taylor J S. Adult linear IgA disease associated with an erythema multiforme-like drug reaction. Cleve Clin J Med 1987; 54: 445–450
   PubMed Web of Science ®Google Scholar
• Chorzelski T P, Jablonska S, Beutner E H. Linear IgA bullous dermatosis. Immunopathology and the Skin, E H Beutner, T P Chorzelski, S F Bean. John Wiley, New York, NY 1979; 315–323
   Google Scholar